{"product_id":"oricpharma-swot-analysis","title":"ORIC Pharmaceuticals SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eORIC Pharmaceuticals' potential lies in its innovative pipeline, but understanding its competitive landscape and potential regulatory hurdles is crucial. Our comprehensive SWOT analysis delves into these core areas, providing a clear roadmap for navigating the biopharmaceutical industry.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind ORIC Pharmaceuticals' strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Focus on Therapeutic Resistance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORIC Pharmaceuticals has a distinct advantage by concentrating on overcoming therapeutic resistance in cancer. This specialized approach targets a significant unmet need, as drug resistance frequently compromises the efficacy of existing cancer therapies.\u003c\/p\u003e\n\u003cp\u003eThis focused strategy aims to develop treatments that can enhance patient outcomes, particularly for those battling challenging or advanced cancers. For instance, the company’s lead candidate, ORIC-533, is designed to address resistance to targeted therapies in solid tumors, a critical area where new solutions are desperately needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Clinical Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORIC Pharmaceuticals possesses a robust clinical-stage pipeline, highlighted by its lead candidates ORIC-114 and ORIC-944.  ORIC-114, a brain-penetrant inhibitor targeting EGFR\/HER2, is being developed for non-small cell lung cancer. \u003c\/p\u003e\n\u003cp\u003eORIC-944, a selective allosteric PRC2 inhibitor, shows promise for metastatic castration-resistant prostate cancer.  Early data for both programs indicate encouraging safety and efficacy profiles, with ORIC-944 specifically demonstrating potential best-in-class attributes and notable prostate-specific antigen (PSA) response rates in mCRPC patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships with Major Pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eORIC Pharmaceuticals has forged significant strategic alliances with industry giants like Johnson \u0026amp; Johnson and Bayer. These collaborations are crucial, especially for their promising candidates ORIC-114 and ORIC-944.\u003c\/p\u003e\n\u003cp\u003eThese partnerships serve as a strong endorsement of ORIC's innovative pipeline, validating the potential of their product candidates. They also pave the way for more extensive clinical trials and can significantly speed up both the development process and market entry by tapping into the vast resources and deep expertise of these larger pharmaceutical players.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolid Financial Runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eORIC Pharmaceuticals boasts a robust financial foundation, providing significant operational flexibility. As of March 31, 2025, the company held approximately $224 million in cash, cash equivalents, and investments. This substantial capital is projected to sustain operations well into 2027, offering a considerable cash runway.\u003c\/p\u003e\n\u003cp\u003eThis financial strength is further reinforced by a successful $125 million private placement completed in 2024. The infusion of capital ensures ORIC can adequately fund its current and upcoming clinical trials without the immediate pressure of seeking additional, potentially dilutive, financing rounds. This stability is crucial for uninterrupted progress in their research and development pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNumerous Upcoming Clinical Milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eORIC Pharmaceuticals is well-positioned with numerous upcoming clinical milestones. The company expects significant data readouts for its ORIC-114 and ORIC-944 programs within the next 15 to 18 months. \u003c\/p\u003e\n\u003cp\u003eThese anticipated results are critical catalysts for future development. Furthermore, ORIC is targeting the potential initiation of registrational (Phase 3) trials for both of these key programs in 2026. This aggressive timeline highlights the company's rapid progression towards late-stage clinical development and potential market entry.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eUpcoming Data Readouts:\u003c\/strong\u003e ORIC-114 and ORIC-944 programs expected to yield significant data within 15-18 months.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegistrational Trial Initiation:\u003c\/strong\u003e Potential for Phase 3 trials for both programs to commence in 2026.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCatalyst for Value:\u003c\/strong\u003e These milestones represent key drivers for company progress and increased valuation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing cancer therapies: Promising clinical data and strong financial outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eORIC Pharmaceuticals' focused strategy on overcoming therapeutic resistance in cancer addresses a critical unmet medical need, enhancing the potential for improved patient outcomes in challenging cases. The company's lead candidates, ORIC-114 and ORIC-944, demonstrate promising early-stage data for non-small cell lung cancer and metastatic castration-resistant prostate cancer, respectively. Strategic partnerships with industry leaders like Johnson \u0026amp; Johnson and Bayer validate ORIC's innovative pipeline and provide crucial resources for accelerated development and market access.\u003c\/p\u003e\n\u003cp\u003eThe company's financial health is robust, with approximately $224 million in cash, cash equivalents, and investments as of March 31, 2025, providing a projected runway into 2027. This stability, bolstered by a $125 million private placement in 2024, allows for uninterrupted progression of clinical trials. Key upcoming milestones include significant data readouts for ORIC-114 and ORIC-944 within the next 15-18 months, with potential Phase 3 trial initiations targeted for 2026, presenting significant catalysts for value appreciation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eKey Upcoming Milestone\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eORIC-114\u003c\/td\u003e\n\u003ctd\u003eNon-small cell lung cancer (NSCLC)\u003c\/td\u003e\n\u003ctd\u003eClinical-stage\u003c\/td\u003e\n\u003ctd\u003eData readout within 15-18 months; Potential Phase 3 initiation in 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eORIC-944\u003c\/td\u003e\n\u003ctd\u003eMetastatic castration-resistant prostate cancer (mCRPC)\u003c\/td\u003e\n\u003ctd\u003eClinical-stage\u003c\/td\u003e\n\u003ctd\u003eData readout within 15-18 months; Potential Phase 3 initiation in 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of ORIC Pharmaceuticals’s internal and external business factors, highlighting its promising pipeline and potential market opportunities while acknowledging development risks and competitive pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a clear, actionable SWOT analysis to pinpoint and address ORIC Pharmaceuticals' key pain points for strategic growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-Stage Company with No Approved Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a clinical-stage biopharmaceutical company, ORIC Pharmaceuticals currently lacks any approved products, meaning it generates no revenue from sales. This absence of commercialized products makes its financial health entirely reliant on the successful progression and eventual market approval of its investigational therapies.  The inherent risks of drug development are therefore magnified without any existing revenue streams to offset operational costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Research and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORIC Pharmaceuticals faces a significant hurdle with its high research and development (R\u0026amp;D) expenses. Advancing multiple product candidates through the rigorous clinical trial process demands substantial financial commitment.\u003c\/p\u003e\n\u003cp\u003eFor the fiscal year ending December 31, 2024, the company reported R\u0026amp;D expenses amounting to $114.1 million. This trend continued into the first quarter of 2025, with expenses increasing due to higher external costs and expanded personnel. These considerable outlays directly contribute to the company's ongoing net losses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Clinical Trial Success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eORIC Pharmaceuticals' future is intrinsically tied to the success of its clinical trials.  Any negative results, unexpected side effects, or delays in the ongoing trials for its lead candidates, such as ORIC-533 and ORIC-101, could severely impact its financial standing and development pipeline.\u003c\/p\u003e\n\u003cp\u003eFor instance, if trials do not meet their primary endpoints, as seen with some other biotechs in early 2024, the company's valuation could plummet, potentially jeopardizing future funding rounds and its ability to advance its research programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNegative Earnings Per Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eORIC Pharmaceuticals has a consistent track record of negative earnings per share (EPS). As of March 31, 2025, the company's trailing 12-month EPS stood at -$1.87. This persistent unprofitability means ORIC relies heavily on external funding for its research and development activities.\u003c\/p\u003e\n\u003cp\u003eThe first quarter of 2025 saw ORIC report a net loss of $0.51 per share. While this is typical for companies in the clinical-stage biotechnology sector, the ongoing losses highlight the absence of current profitability. Such a situation necessitates continuous access to capital to sustain operations and advance its pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eNegative EPS:\u003c\/strong\u003e Trailing 12-month EPS of -$1.87 as of March 31, 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQ1 2025 Performance:\u003c\/strong\u003e Reported a net loss of $0.51 per share.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Dependence:\u003c\/strong\u003e Relies on external financing due to ongoing losses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition in Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe oncology sector is exceptionally crowded, with many large, established pharmaceutical giants and nimble biotech firms all competing fiercely for market share. ORIC Pharmaceuticals operates within this intense environment, facing rivals who are also developing treatments for cancer, including those specifically targeting drug resistance mechanisms. This crowded field could significantly affect how easily ORIC’s potential therapies can gain traction in the market and influence their ability to set prices once approved.\u003c\/p\u003e\n\u003cp\u003eFor instance, in 2024, the global oncology market was valued at over $200 billion, with significant investment flowing into research and development. ORIC’s pipeline, particularly its focus on overcoming resistance, places it directly against numerous players with advanced clinical programs. Companies like Pfizer, Bristol Myers Squibb, and Merck, among many others, have substantial oncology portfolios and R\u0026amp;D budgets, presenting a formidable competitive barrier.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Saturation:\u003c\/strong\u003e The oncology drug market is highly saturated, with numerous approved therapies and many more in development.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRival Pipeline Focus:\u003c\/strong\u003e Competitors are also actively developing drugs aimed at overcoming treatment resistance, a key area for ORIC.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePricing Pressure:\u003c\/strong\u003e Intense competition can lead to pricing pressures, potentially impacting the revenue potential of ORIC's future products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEstablished Players:\u003c\/strong\u003e Large pharmaceutical companies with existing oncology franchises and significant market presence pose a substantial competitive threat.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExternal Funding Critical for Sustaining Operations Amidst Losses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eORIC Pharmaceuticals' reliance on external funding is a significant weakness, as evidenced by its consistent negative EPS, which was -$1.87 on a trailing 12-month basis as of March 31, 2025. The company reported a net loss of $0.51 per share in Q1 2025, underscoring its lack of current profitability and the critical need for continuous capital infusion to sustain operations and advance its drug candidates.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eORIC Pharmaceuticals SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual ORIC Pharmaceuticals SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. It details the company's internal Strengths and Weaknesses, alongside external Opportunities and Threats, providing a comprehensive overview for strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610624311673,"sku":"oricpharma-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/oricpharma-swot-analysis.png?v=1754741753","url":"https:\/\/matrixbcg.com\/products\/oricpharma-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}